FAMILIAL INTRAHEPATIC CHOLESTASIS IN CHILDREN: PROBLEMS AND PROSPECTS

The review presents various aspects of the clinic and diagnosis of familial intrahepatic cholestasis (FIC) in children, including such forms of liver pathology as progressive FIC (PFIC) types 1-5; PFIC associated with mutations in the MYO5B gene; non-progressive forms of intrahepatic cholestasis (benign recurrent IC, gestational IC, drug-induced cholestasis, hypophospholipid-associated cholelithiasis and liver cancer accompanied by cholestasis). The main methods for the diagnosis and treatment of cholestatic diseases in children are described. The feasibility of using full-exomic sequencing for the accurate diagnosis of HPV in children is shown.

Morotti RA, Suchy FJ, Magid MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis. 2011;31(1):3-10. doi: 10.1055/s-0031-1272831.

Hori T, Nguyen JH, Uemoto S. Progressive familial intrahepatic cholestasis. Hepatobiliary Pancreat Dis Int. 2010;9(6):570-8. PMID: 21134824

Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L. et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr. 2011;52(1):73-83. doi: 10.1097/MPG.0b013e3181f50363.

Degiorgio D, Crosignani A, Colombo C, Bordo D, Zuin M, Vassallo E, et al. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. J Gastroenterol. 2016;51(3):271-80. doi: 10.1007/s00535-015-1110-z.

Gordo-Gilart R, Hierro L, Andueza S, Muñoz-Bartolo G, López C, Díaz C, et al. Heterozygous ABCB4 mutations in children with cholestatic liver disease. Liver Int. 2016;36(2):258-67. doi: 10.1111/liv.12910.

Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006;44(2):478-86. doi: 10.1002/hep.21287

Sambrotta M, Thompson RJ. Mutations in TJP2, encoding zona occludens 2, and liver disease. Tissue Barriers. 2015;3(3):e1026537. doi: 10.1080/21688370.2015.1026537.

Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim MS, Kim KH, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713. doi: 10.1038/ncomms10713.

Herbst SM, Schirmer S, Posovszky C, Jochum F, Rödl T, Schroeder JA. et al. Taking the next step forward - Diagnosing inherited infantile cholestatic disorders with next generation sequencing. Mol Cell Probes. 2015;29(5):291-8. doi: 10.1016/j.mcp.2015.03.001.

Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46(4):326-8. doi: 10.1038/ng.2918.

Qiu YL, Gong JY, Feng JY, Wang RX, Han J, Liu T, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis. Hepatology. 2017;65(5):1655-1669. doi: 10.1002/hep.29020.

Gonzales E, Taylor SA, Davit-Spraul A, Thébaut A, Thomassin N, Guettier C. et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology. 2017;65(1):164-73. doi: 10.1002/hep.28779.

Paulusma CC, Elferink RP, Jansen PL. Progressive familial intrahepatic cholestasis type 1. Semin Liver Dis. 2010;30(2):117-24. doi: 10.1055/s-0030-1253221.

Gonzales E, Grosse B, Schuller B, Davit-Spraul A, Conti F, Guettier C. et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology. 2015;62(2):558-66. doi: 10.1002/hep.27767.

Naoi S, Hayashi H, Inoue T, Tanikawa K, Igarashi K, Nagasaka H, et al. Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. J Pediatr. 2014;164(5):1219-1227.e3. doi: 10.1016/j.jpeds.2013.12.032.

Varma S, Revencu N, Stephenne X, Scheers I, Smets F, Beleza-Meireles A, et al. Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2. Hepatology. 2015;62(1):198-206. doi: 10.1002/hep.27834.

Kubitz R, Dröge C, Stindt J, Weissenberger K, Häussinger D. The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol. 2012;36(6):536-53. doi: 10.1016/j.clinre.2012.06.006.

Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L. et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr. 2011;52(1):73-83. doi: 10.1097/MPG.0b013e3181f50363.

Degiorgio D, Crosignani A, Colombo C, Bordo D, Zuin M, Vassallo E. et al. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. J Gastroenterol. 2016;51(3):271-80. doi: 10.1007/s00535-015-1110-z.

Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis. 2010;30(2):134-46. doi: 10.1055/s-0030-1253223.

Keitel V, Burdelski M, Warskulat U, Kühlkamp T, Keppler D, Häussinger D. et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology. 2005;41(5):1160-72. doi: 10.1002/hep.20682

Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M. et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology. 1997;25(3):519-23. doi: 10.1002/hep.510250303

Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol. 2010;52(2):258-71. doi: 10.1016/j.jhep.2009.11.012.

Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2014;4(1):25-36. doi: 10.1016/j.jceh.2013.10.005.

Davis AR, Rosenthal P, Newman TB. Nontransplant surgical interventions in progressive familial intrahepatic cholestasis. J Pediatr Surg. 2009;44(4):821-7. doi: 10.1016/j.jpedsurg.2008.07.018.

Lykavieris P, van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol. 2003;39(3):447-52.

Siebold L, Dick AA, Thompson R, Maggiore G, Jacquemin E, Jaffe R, et al. Recurrent low gamma-glutamyl transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (posttransplant recurrent BSEP disease). Liver Transpl. 2010;16(7):856-63. doi: 10.1002/lt.22074.

Stindt J, Kluge S, Dröge C, Keitel V, Stross C, Baumann U. et al. Bile salt export pump-reactive antibodies form a polyclonal, multi-inhibitory response in antibody-induced bile salt export pump deficiency. Hepatology. 2016;63(2):524-37. doi: 10.1002/hep.28311.

Misawa T, Hayashi H, Makishima M, Sugiyama Y, Hashimoto Y. E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity. Bioorg Med Chem Lett. 2012;22(12):3962-6. doi: 10.1016/j.bmcl.2012.04.099.

Folvik G, Hilde O, Helge GO. Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases. Scand J Gastroenterol. 2012;47(4):482-8. doi: 10.3109/00365521. 2011.650191.

Lam P, Soroka CJ, Boyer JL. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis. 2010;30(2):125-33. doi: 10.1055/s-0030-1253222.

Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 2004;8(1):133-49, vii. doi: 10.1016/S1089-3261(03)00133-8

Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs. 2002;26(2):103-10.

Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, Loret-de-Mola O, Nahmad M, Burnweit CA. Ileal exclusion for Byler’s disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg. 1998;33(2):220-4.

Stindt J, Ellinger P, Weissenberger K, Dröge C, Herebian D, Mayatepek E, et al. A novel mutation within a transmembrane helix of the bile salt export pump (BSEP, ABCB11) with delayed development of cirrhosis. Liver Int. 2013;33(10):1527-35. doi: 10.1111/liv.12217.

van der Woerd WL, van Mil SW, Stapelbroek JM, Klomp LW, van de Graaf SF, Houwen RH. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol. 2010;24(5):541-53. doi: 10.1016/j.bpg.2010.07.010.

Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol. 2016;64(4):933-45. doi: 10.1016/j.jhep.2015.11.030.

Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J. et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899-909. doi: 10.1016/S0140-6736(18)31877-4.

Williamson C, Hems LM, Goulis DG, Walker I, Chambers J, Donaldson O. et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG. 2004;111(7):676-81. doi: 10.1111/j.1471-0528.2004.00167.x.

Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol. 2006;44(6):1150-7. doi: 10.1016/j.jhep.2005.09.017

Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014;124(1):120-33. doi: 10.1097/AOG.0000000000000346.

Pauli-Magnus C, Meier PJ, Stieger B. Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Semin Liver Dis. 2010;30(2):147-59. doi: 10.1055/s-0030-1253224.

Schneider G, Paus TC, Kullak-Ublick GA, Meier PJ, Wienker TF, Lang T. et al. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology. 2007;45(1):150-8. doi: 10.1002/hep.21500

Painter JN, Savander M, Ropponen A, Nupponen N, Riikonen S, Ylikorkala O. et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet. 2005;13(4):435-9. doi: 10.1038/sj.ejhg.5201355

Dixon PH, Sambrotta M, Chambers J, Taylor-Harris P, Syngelaki A, Nicolaides K, et al. An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep. 2017;7(1):11823. doi: 10.1038/s41598-017-11626-x.

Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study). Medicine (Baltimore). 2016;95(40):e4949. doi: 10.1097/MD.0000000000004949.

Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(Suppl.1):25-37. doi: 10.1016/j.jhep.2015.02.023.

Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology. 2005;129(3):894-901. doi: 10.1053/j.gastro.2005.06.019

Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomäki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology. 2006;43(4):723-8. doi: 10.1002/hep.21111

Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology. 2011;53(4):1377-87. doi: 10.1002/hep.24229.

Nakanishi Y, Saxena R. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System. Arch Pathol Lab Med. 2015;139(7):858-66. doi: 10.5858/arpa.2014-0229-RA.

Garzel B, Yang H, Zhang L, Huang SM, Polli JE, Wang H. The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metab Dispos. 2014;42(3):318-22. doi: 10.1124/dmd.113.054189.

Dröge C, Bonus M, Baumann U, Klindt C, Lainka E, Kathemann S, et al. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants. J Hepatol. 2017;67(6):1253-64. doi: 10.1016/j.jhep.2017.07.004

Vitale G, Gitto S, Raimondi F, Mattiaccio A, Mantovani V, Vukotic R, et al. Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing. J Gastroenterol. 2018;53(8):945-58. doi: 10.1007/s00535-017-1423-1.

Bessone F, Robles-Diaz M, Hernandez N, Medina-Caliz I, Lucena MI, Andrade RJ. Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. Semin Liver Dis. 2019. doi: 10.1055/s-0039-1685519.

Lucena MI, García-Cortés M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008;22(2):141-58. doi: 10.1111/j.1472-8206.2008.00566.x.

Danan G, Teschke R. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future. Front Pharmacol. 2019;10:853. doi: 10.3389/fphar.2019.00853

Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis. 2007;11(2):29. doi: 10.1186/1750-1172-2-29

Erlinger S. Low phospholipid-associated cholestasis and cholelithiasis. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):36-40. doi:10.1016/S2210-7401(12)70019-0.

Poupon R, Rosmorduc O, Boëlle PY, Chrétien Y, Corpechot C, Chazouillères O. et al. Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients. Hepatology. 2013;58(3):1105-10. doi: 10.1002/hep.26424.

Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerová D, Rayner A, Dutton L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134(4):1203-14. doi: 10.1053/j.gastro.2008.01.038.

Bass LM, Patil D, Rao MS, Green RM, Whitington PF. Pancreatic adenocarcinoma in type 2 progressive familial intrahepatic cholestasis. BMC Gastroenterol. 2010;10:30. doi: 10.1186/1471-230X-10-30.

Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res. 2005;589(1):47-65. doi: 10.1016/j.mrrev.2004.08.001

Scheimann AO, Strautnieks SS, Knisely AS, Byrne JA, Thompson RJ, Finegold MJ. Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma. J Pediatr. 2007;150(5):556-9. doi: 10.1016/j.jpeds.2007.02.030

Zhou S, Hertel PM, Finegold MJ, Wang L, Kerkar N, Wang J. et al. Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. Hepatology. 2015;62(6):1914-6. doi: 10.1002/hep.27872.